Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer.
Vultaggio A, Petrella MC, Tomao F, Nencini F, Mecheri V, Marini A, Perlato M, Vivarelli E, De Angelis C, Ferrarini I, Pillozzi S, Matucci A, Antonuzzo L. Vultaggio A, et al. Among authors: petrella mc. Gynecol Oncol Rep. 2021 Oct 12;38:100880. doi: 10.1016/j.gore.2021.100880. eCollection 2021 Nov. Gynecol Oncol Rep. 2021. PMID: 34926761 Free PMC article.
First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.
Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P. Tomao F, et al. Among authors: petrella mc. Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874. eCollection 2020. Cancer Manag Res. 2020. PMID: 32765062 Free PMC article. Review.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, Valabrega G. Tuninetti V, et al. Among authors: petrella mc. Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30. Eur J Cancer. 2024. PMID: 38598922
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB. Tomao F, et al. Among authors: petrella mc. Cancer Treat Rev. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9. Cancer Treat Rev. 2019. PMID: 31629204 Review.
Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Tomao F, Santangelo G, Musacchio L, Di Donato V, Fischetti M, Giancotti A, Perniola G, Petrella MC, Monti M, Palaia I, Muzii L, Benedetti Panici P. Tomao F, et al. Among authors: petrella mc. J Cell Physiol. 2020 Jun;235(6):5050-5058. doi: 10.1002/jcp.29440. Epub 2020 Jan 8. J Cell Physiol. 2020. PMID: 31912897 Review.
26 results